Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Should We Screen Patients With HIV for NAFLD/NASH?

In this podcast episode, listen to hepatologist Giada Sebastiani, MD, discuss why the presence of obesity, metabolic syndrome, persistent elevation of ALT, or exposure to dideoxynucleoside analogues should trigger an evaluation for NAFLD and NASH, particularly in our aging population of patients with HIV.
Giada Sebastiani, MD
Released: November 10, 2021

In this episode, hepatologist Giada Sebastiani, MD, discusses why the presence of obesity, metabolic syndrome, persistent elevation of ALT, or exposure to dideoxynucleoside analogues can trigger an evaluation for NAFLD and NASH, particularly in our aging population of patients with HIV with topics including:

  • Metabolic factors  
  • HIV-related factors
  • Which patients with HIV are at risk

Information on this Educational Activity

Faculty

Giada Sebastiani, MD

Associate Professor of Medicine
McGill University Health Centre
Division of Gastroenterology and Hepatology and Division of Infectious Diseases
Clinician Scientist
Research Institute of McGill University Health Centre
Montreal, Quebec, Canada

Giada Sebastiani, MD, has disclosed that she has received funds for research support from Merck and Theratec; consulting fees from Allergan, Intercept, Gilead Sciences, Merck, Novartis, Novo Nordisk, and Pfizer; and fees for non-CME/CE services from AbbVie, Gilead Sciences, Merck, Novartis, Novo Nordisk, and Pfizer.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by
Theratechnologies Inc.

Related Content

Experts discuss practical use of CGM in clinical practice, with a focus on overcoming barriers to integration, from Clinical Care Options (CCO)

Martin J. Abrahamson, MD, FACP
Program Director
Leslie Eiland, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Physician Assistants: maximum of 1.0 hour of AAPA Category 1 CME credit Released: May 27, 2022 Expired: May 26, 2023

Expert faculty summarize key evidence for finerenone use in diabetic kidney disease, selecting patients for therapy, and the role of the pharmacist, from ProCE

Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP Released: May 17, 2022

Clinical Care Options (CCO) presents Dr. Jane Jeffrie Seley discussing the importance of patient education and training when managing T2D treatment in older patients

Jane Jeffrie Seley, DNP, MPH, MSN, GNP, BC-ADM, CDCES Released: May 4, 2022

Expert faculty insight on evidence for finerenone use in DKD, selecting patients for therapy, overcoming clinical inertia, from ProCE

Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP Pharmacists: 1.5 contact hours (0.15 CEUs) Released: April 29, 2022 Expired: April 28, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings